Status:
COMPLETED
Safety of EVG+RTV Administered With Other Antiretroviral Agents for the Treatment of HIV-1 Infection
Lead Sponsor:
Gilead Sciences
Conditions:
HIV Infections
Eligibility:
All Genders
Phase:
PHASE2
Brief Summary
The main objective of this study is to observe the long-term safety of elvitegravir (EVG) boosted with ritonavir (RTV) in combination with other antiretroviral (ARV) agents in participants who have co...
Eligibility Criteria
Inclusion
- Completion of a prior EVG+RTV treatment study without treatment-limiting toxicity.
- Males and females of childbearing potential must agree to utilize effective contraception methods.
- Ability to understand and sign a written informed consent form.
Exclusion
- Females who are pregnant or breastfeeding.
- Participation in any other clinical trial without prior approval from the Sponsor.
- Any other clinical condition or prior therapy that, in the opinion of the investigator, would make the subject unsuitable for the study.
- Subjects receiving ongoing therapy with contraindicated drugs.
Key Trial Info
Start Date :
February 1 2007
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
March 1 2015
Estimated Enrollment :
192 Patients enrolled
Trial Details
Trial ID
NCT00445146
Start Date
February 1 2007
End Date
March 1 2015
Last Update
April 25 2016
Active Locations (48)
Enter a location and click search to find clinical trials sorted by distance.
1
Pheonix, Arizona, United States, 85006
2
Little Rock, Arkansas, United States, 72207
3
Beverly Hills, California, United States, 90211
4
Costa Mesa, California, United States, 92626